← Back to Patent Explorer
US4747847A Expired / Lapsed US ⏱️ 0.0 years remaining

System for delivering potassium chloride with enhanced bioacceptability

Assignee: Alza Corp
•
Filing: 1987-07-09
•
Granted: 1988-05-31
•
Expires: 2007-07-09
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A composition of matter comprising a drug, a neutral hydrogel and an ionic hydrogel. The composition can be administered from a delivery system to a biological receptor over time.

Inventors

  • 👤 Paul R. Magruder
  • 👤 Patrick S. L. Wong
  • 👤 Felix Theeuwes
  • 👤 George V. Guittard

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-26 22:19
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0002; A61K9/0004; A61M; A61M31/00; A61M31/002

Claims Analysis

Total Claims: 7
Claim 1
Independent Claim 206 words
A dosage form for delivering a beneficial drug to a fluid biological environment for use, the dosage form comprising: (a) a wall comprising in at least a part a semipermeable composition permeable to the passage of fluid and substantially impermeable to the passage of drug, which wall surrounds and forms; (b) a compartment housing a composition comprising (1) a therapeutically effective dose of the beneficial drug potassium chloride blended with (2) means for aiding in delivering the potassium chloride from the compartment and for lessening the incidence of unwanted side effects of potassium chloride on the bioloical environment of use, said means comprising a first hydrogel and a different second hydrogel; (c) at least one passageway in the wall communicating with the compartment and the exterior of the dosage form for delivering the composition comprising the potassium chloride and the means from the dosage form over a prolonged period of time; and, (d) wherein, when the dosage form is in operation in the environment of use, the dosage form delivers the composition comprising the potassium chloride and the means comprising the first and second hydrogels for the potassium chloride therapeutic effects and for simultaneously lessening the incidence of unwatned side effects on the environment of use.
Claim 2
Dependent Claim 206 words
A dosage form for delivering a beneficial drug to a fluid biological environment for use, the dosage form comprising: (a) a wall comprising in at least a part a semipermeable composition permeable to the passage of fluid and substantially impermeable to the passage of drug, which wall surrounds and forms; (b) a compartment housing a composition comprising (1) a therapeutically effective dose of the beneficial drug potassium chloride blended with (2) means for aiding in delivering the potassium chloride from the compartment and for lessening the incidence of unwanted side effects of potassium chloride on the bioloical environment of use, said means comprising a first hydrogel and a different second hydrogel; (c) at least one passageway in the wall communicating with the compartment and the exterior of the dosage form for delivering the composition comprising the potassium chloride and the means from the dosage form over a prolonged period of time; and, (d) wherein, when the dosage form is in operation in the environment of use, the dosage form delivers the composition comprising the potassium chloride and the means comprising the first and second hydrogels for the potassium chloride therapeutic effects and for simultaneously lessening the incidence of unwatned side effects on the environment of use.
Claim 3
Dependent Claim 154 words
A dosage form for delivering the beneficial drug potassium chloride to an animal, the dosage form comprising: (a) a wall comprising cellulose acetate and polyethylene glycol which wall is permeable to the passage of fluid and substantially impermeable to the passage of potassium chloride, which wall surrounds and forms; (b) a compartment containing a composition comprising (1) a therapeutically effective amount of potassium chloride, (2) potassium carboxypolymethylene and (3) polyethylene oxide; (c) at least one passageway in the wall communicating with the compartment and the exterior of the dosage form for delivering the composition comprising potassium chloride, potassium carboxypolymethylene and polyethylene oxide to the animal over a prolonged period of time; and, (d) wherein, when the dosage form is in operation in the animal it delivers the composition comprising potassium chloride for its beneficial effects and, concomitantly, potassium carboypolymethylene and polyethylene oxide for lessening the incidence of irritation of mucosal tissue of the animal.
Claim 4
Dependent Claim 154 words
A dosage form for delivering the beneficial drug potassium chloride to an animal, the dosage form comprising: (a) a wall comprising cellulose acetate and polyethylene glycol which wall is permeable to the passage of fluid and substantially impermeable to the passage of potassium chloride, which wall surrounds and forms; (b) a compartment containing a composition comprising (1) a therapeutically effective amount of potassium chloride, (2) potassium carboxypolymethylene and (3) polyethylene oxide; (c) at least one passageway in the wall communicating with the compartment and the exterior of the dosage form for delivering the composition comprising potassium chloride, potassium carboxypolymethylene and polyethylene oxide to the animal over a prolonged period of time; and, (d) wherein, when the dosage form is in operation in the animal it delivers the composition comprising potassium chloride for its beneficial effects and, concomitantly, potassium carboypolymethylene and polyethylene oxide for lessening the incidence of irritation of mucosal tissue of the animal.
Claim 5
Dependent Claim 34 words
The dosage form for delivering the benefical drug potassium chloride according to claim 1, wherein the passageway is a pore and the dosage form comprises from 50 mg to 750 mg of potassium chloride.
Claim 6
Dependent Claim 35 words
The dosage form for delivering the beneficial drug potassium chloride according to claims 1, wherein the passageway is a pore, the wall comprises lactose, and the dosage form delivers potassium chloride for reversing potassium depletion.
Claim 7
Dependent Claim 41 words
The dosage form for delivering the beneficial drug potassium chloride according to claim 1, wherein the passageway is a pore, the wall comprises sorbitol, and the dosage form delivers potassium chloride for aiding in maintaining the potassium requirement of the animal.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1991-05-31 1991-11-30 1992-05-31 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1995-05-31 1995-11-30 1996-05-31 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1999-05-31 1999-11-30 2000-05-31 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag